GSA Capital Partners LLP Increases Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

GSA Capital Partners LLP lifted its position in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 283.3% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 67,746 shares of the biopharmaceutical company's stock after purchasing an additional 50,072 shares during the period. GSA Capital Partners LLP owned 0.11% of Sage Therapeutics worth $539,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Sage Therapeutics in the first quarter valued at approximately $347,000. GAMMA Investing LLC raised its stake in Sage Therapeutics by 16,118.0% in the first quarter. GAMMA Investing LLC now owns 8,109 shares of the biopharmaceutical company's stock worth $64,000 after buying an additional 8,059 shares in the last quarter. CWM LLC raised its stake in Sage Therapeutics by 1,943.1% in the first quarter. CWM LLC now owns 61,416 shares of the biopharmaceutical company's stock worth $488,000 after buying an additional 58,410 shares in the last quarter. Millennium Management LLC raised its stake in Sage Therapeutics by 8.3% in the fourth quarter. Millennium Management LLC now owns 1,623,785 shares of the biopharmaceutical company's stock worth $8,817,000 after buying an additional 124,720 shares in the last quarter. Finally, ProShare Advisors LLC raised its stake in Sage Therapeutics by 31.2% in the fourth quarter. ProShare Advisors LLC now owns 18,281 shares of the biopharmaceutical company's stock worth $99,000 after buying an additional 4,350 shares in the last quarter. Hedge funds and other institutional investors own 99.22% of the company's stock.

Sage Therapeutics Stock Performance

NASDAQ:SAGE opened at $8.68 on Tuesday. Sage Therapeutics, Inc. has a one year low of $4.62 and a one year high of $11.44. The firm has a market cap of $543.54 million, a price-to-earnings ratio of -1.78 and a beta of 0.26. The firm's fifty day moving average is $8.38 and its two-hundred day moving average is $7.68.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The biopharmaceutical company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.96) by $0.17. Sage Therapeutics had a negative net margin of 427.78% and a negative return on equity of 67.10%. The company had revenue of $31.66 million for the quarter, compared to analyst estimates of $16.69 million. During the same period in the prior year, the company earned ($1.70) earnings per share. The firm's revenue was up 266.0% on a year-over-year basis. As a group, equities research analysts predict that Sage Therapeutics, Inc. will post -3.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on SAGE. Wall Street Zen raised Sage Therapeutics to a "hold" rating in a research report on Saturday. Piper Sandler downgraded Sage Therapeutics from a "strong-buy" rating to a "hold" rating and reduced their price target for the stock from $9.00 to $8.50 in a research report on Tuesday, June 17th. HC Wainwright reaffirmed a "neutral" rating and set a $12.00 price target on shares of Sage Therapeutics in a research report on Tuesday, June 17th. Truist Financial set a $9.00 price target on Sage Therapeutics and gave the stock a "hold" rating in a research report on Tuesday, June 17th. Finally, Scotiabank downgraded Sage Therapeutics from a "strong-buy" rating to a "hold" rating and reduced their price target for the stock from $12.00 to $9.20 in a research report on Tuesday, July 8th. One equities research analyst has rated the stock with a sell rating and fifteen have assigned a hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $8.02.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.